CrushSCI.com
123.6平均天数
97中位天数
60最短天数
538最长天数
4082025发文量

Paper Review Records

全部论文审稿周期

16 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

96 天

CD74 links MHC class II risk to tumor immune microenvironment remodeling across the Sjögren-to-lymphoma axis

作者
Shuyuan Liu; Meng Li; Yingying Wang; Xinhao Xia; Peiying Wang; Zhijie Ni; Qingyun Li; Qifei Teng; Wenlin Han; Jiani Liu; Xiaodong Wang; Sheng Yu; Hui Zhang; Xiangxin Meng; Fei Zhong; Hao Wang展开收起
作者单位
The Affiliated Guangzhou Hospital of TCM of Guangzhou University of Chinese Medicine, Guangzhou, 510000, Guangdong, China; Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China; Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, Guangdong, China; The First School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China; School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510515, Guangdong, China; School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, Guangdong, China; Department of Traditional Chinese Internal Medicine, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, Guangdong, China展开收起
PDF源文件 DOI 网页
124 天

MF1, a novel robustic acid derivative, exerts antitumor effects in hepatocellular carcinoma

作者
Juanjuan Huang; Lijuan Teng; Tianxiu Meng; Yuqiong Liang; Yaoqi Li; Jinyan Lv展开收起
作者单位
Faculty of Chinese Medicine Science, Guangxi University of Chinese Medicine, Nanning, Guangxi Zhuang Autonomous Region, 530004, China; Krirk University, Bangkhen, Bangkok, 10220, Thailand; School of Public Health, Yale University, New Haven, CT, 06510, USA展开收起
PDF源文件 DOI 网页
143 天

The CARM1–YIPF2 axis drives breast cancer progression and predicts poor prognosis

作者
Xitao Gao; Shuchang Zhang; Wei Peng; Kun Xu展开收起
作者单位
Department of Breast Surgery, The Affiliated Lianyungang Hospital of Xuzhou Medical University, The First People's Hospital of Lianyungang, Lianyungang, 222002, China; Department of Breast Surgery, The Affiliated Hospital of Kangda College of Nanjing Medical University, The First People's Hospital of Lianyungang, Lianyungang, 222002, China; Department of Breast Surgery, Lianyungang Clinical College of Nanjing Medical University, The First People's Hospital of Lianyungang, Lianyungang, 222002, China; Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research, 42 Baiziting, Nanjing, 210009, China; Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, 42 Baiziting, Nanjing, 210009, China展开收起
PDF源文件 DOI 网页
538 天

Aggressive features and immune landscape of macrotrabecular hepatocellular carcinoma

作者
Lixia Wu; Meidan Li; Xuefang Wang; Qionglan Wu; Yi Chen; Bin Wang; Lihong Chen展开收起
作者单位
Department of Pathology, Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, Fujian, 350025, China; Department of Pathology and Institute of Oncology, The School of Basic Medical Sciences, Fujian Medical University, Fuzhou, Fujian, 350004, China展开收起
PDF源文件 DOI 网页
60 天

A renal cyst-clear cell renal cell carcinoma comorbidity analysis identifies a FOXM1-positive epithelial COL6A1-CD44 axis that remodels fibroblasts

作者
Hao Lv; Chenyi Ge; Yuming Jin; Yu Fang; Wenqiang Liu; Yan Zhang; Hanzhong Zhang; Chencan Fang; Le Qu; Xin Lu; Wentao Zhang; Nan Zhang; Aimin Jiang; Lingfeng Wu; Linhui Wang展开收起
作者单位
Department of Urology, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China; Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China; Department of Urology, The First Naval Hospital of Southern Theater Command, Zhanjiang, China; Department of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China; Department of Urology, Henan Corps Hospital of Chinese People's Armed Police Force, Zhengzhou, Henan, China; Department of Urology, The Frist Hospital of Jiaxing, Frist Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China展开收起
PDF源文件 DOI 网页
68 天

Shared inflammatory-metabolic transcriptional effects in tubulointerstitial fibrosis and clear cell renal cell carcinoma

作者
Sha Tang; Furong Li; Ling Nie; Yinghui Huang; Yiqin Wang; Jinghong Zhao; Yan Li展开收起
作者单位
Department of Nephrology, the Key Laboratory for the Prevention and Treatment of Kidney Disease of Chongqing, Chongqing Clinical Research Center of Kidney and Urology Diseases, Xinqiao Hospital, Army Medical University (Third Military Medical University), Chongqing, 400037, PR China展开收起
PDF源文件 DOI 网页

FAQ

Translational Oncology审稿要多久?

截至2026-11-19,CrushSCI 收录了 Translational Oncology 的 16 篇完整审稿记录。最快一篇从收稿到录用用了 60 天(A renal cyst-clear cell renal cell carcinoma comorbidity analysis identifies a FOXM1-positive epithelial COL6A1-CD44 axis that remodels fibroblasts,2026-07-27 收稿,2026-09-25 录用),最慢一篇用了 538 天;平均 123.6 天,中位数 97 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。